HCP Plastene (526717)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what the numbers actually say. HCP Plastene, a packaging business, has grown sales by only 1.59%, yet reported a 368% jump in profit. As Graham would ask: is this a business getting better, or earnings recovering from a low base? In a competitive industry like packaging, I see no durable moat in these figures. The shares trade at a P/E of 9.55 and a price-to-book of 4.52, meaning I pay ₹179 for book value of ₹39.71. A 28.36% ROE sounds attractive, but the 13.23% ROCE tells me the return on capital is far more modest. Without a debt-to-equity figure, I cannot confidently judge how much leverage is inflating that ROE. The latest quarter shows sales of ₹121 Cr and profit of ₹8 Cr, which is a 6.6% margin. If annualized, that would suggest ₹32 Cr of profit, yet the trailing P/E implies about ₹20 Cr. That inconsistency warns me that earnings are not stable. The 0.56% dividend yield means I am not being paid to wait. The Piotroski score of 7/9 shows some financial strength, but a score is no substitute for a predictable competitive position. The PEG of 0.03 is a trap: profit growth cannot be 368% every year when revenue barely moves. The share price has fallen from ₹284 to ₹179, so the market has already cooled. This is not a compounder yet. It smells more like a turnaround, where one or two good quarters get extrapolated. I would need several quarters of rising sales and sustained margins before calling it a bargain. For now, I watch, I do not chase.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer